MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...

Managed by LifeStance Health. Your call or email may go to a representative. Rose Marie Coleman is a Psychiatric Mental Health Nurse Practitioner (PMHNP) in New York who is passionate about helping ...

Jon Long and Dr Tara Shine are joined by Chris McCausland to tackle the topic of Tech.